دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Editor's Choice – John Ingram – November 2023
doi : 10.1093/bjd/ljad348
British Journal of Dermatology, Volume 189, Issue 5, November 2023, Pages i–ii
Skin is a window to one’s inner world
Viktoria Eleftheriadou 1,2 and Andrew R. Thompson
doi : 10.1093/bjd/ljad300
Is lirentelimab the ‘magic bullet’ to fight pathological mast-cell activation in systemic mastocytosis?
Stéphane Barete and Michel Arock
doi : 10.1093/bjd/ljad227
The role of the immune system in cutaneous T-cell lymphoma; an area requiring more investigation
Alessandro Pileri1,2 and Nicola Pimpinelli
doi : 10.1093/bjd/ljad255
Epidermal necrolysis: a chronic disease associated with loss-of-life expectancy and lifetime healthcare expenditure
Saskia Ingen-Housz-Oro
doi : 10.1093/bjd/ljad254
Filling the gap: investigating the interpretability of the Recap of atopic eczema questionnaire
Robert F. Ofenloch
doi : 10.1093/bjd/ljad287
Ambient-stable topical rapamycin cream is effective in treating angiofibromas in tuberous sclerosis complex
Chien-Hui Hong1,2 and Chih-Hung Lee
doi : 10.1093/bjd/ljad334
Effectiveness of spironolactone for women with acne vulgaris (SAFA) trial: a critically appraised topic
Ali Shields1,2 and John S. Barbieri
doi : 10.1093/bjd/ljad270
Safety and efficacy of lirentelimab in patients with refractory indolent systemic mastocytosis: a first-in-human clinical trial
Frank Siebenhaar,1,2 Sabine Altrichter,1,3 Hanna Bonnekoh,1,2 Tomasz Hawro,1 Marlena Hawro,1 Edward G. Michaelis,1,4 Andrea M. Kantor,5,* Alan T. Chang,5 Bradford A. Youngblood,5 Bhupinder Singh,5,* Henrik S. Rasmussen5,* and Marcus Maurer
doi : 10.1093/bjd/ljad191
A novel rapamycin cream formulation improves facial angiofibromas associated with tuberous sclerosis complex: a double-blind randomized placebo-controlled trial
Phillip Aitken ,1 Ioana Stanescu ,1 Laura Boddington ,1 Caroline Mahon,2 Andras Fogarasi,3 Yi-Hua Liao ,4 Marta Ivars ,5 Ester Moreno-Artero ,5 Doris Trauner,6 Steven T. DeRoos,7 Jasna Jancic ,8,9 Milos Nikolic ,10 Patr?cia Bal??ov?,11 Harper N. Price ,12 Kinga Hadzsiev ,13 Kate Riney,14,15 Stacie Stapleton,16 Megha M. Tollefson,17 Derek Bauer,18 Blanka Pinkov?19 and Hartley Atkinson
doi : 10.1093/bjd/ljad243
Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial
Stephan Weidinger,1 Thomas Bieber,2,3 Michael J. Cork,4 Adam Reich,5 Rosamund Wilson,6 Sonia Quaratino,7 Marisa Stebegg,8 Nuala Brennan,7 Sally Gilbert,9 John T. O’Malley10 and Ben Porter-Brown
doi : 10.1093/bjd/ljad240
Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse)
Linda F. Stein Gold,1 Jerry Bagel,2 Stephen K. Tyring,3 H. Chih-ho Hong,4,5 Lev Pavlovsky,6,7 Ronald Vender ,8,9 Andreas Pinter,10 Adam Reich,11 Leonidas Drogaris,12 Tianshuang Wu,12 Manish Patel,12 Ahmed M. Soliman,12 Huzefa Photowala,12 Vassilis Stakias,12 Sven Richter12 and Kim A. Papp
doi : 10.1093/bjd/ljad252
Lifetime risk, life expectancy, loss-of-life expectancy and lifetime healthcare expenditure for Stevens–Johnson syndrome/toxic epidermal necrolysis in Taiwan: follow-up of a nationwide cohort from 2008 to 2019
Ying-Ming Chiu1,2,3 and Hsien-Yi Chiu
doi : 10.1093/bjd/ljad234
Persistence of second-line biologics in psoriasis after first-line biologic failure: a nationwide cohort study from the French health insurance database (SNDS)
Clarisse Marcombes,1,2 Laetitia Penso,1,2 Alain Weill,2 Rosemary Dray-Spira,2 Mahmoud Zureik2 and Emilie Sbidian
doi : 10.1093/bjd/ljad248
Exploring the natural and treatment history of vitiligo: perceptions of patients and healthcare professionals from the global VALIANT study
Iltefat H. Hamzavi,1 Kristen Bibeau,2 Pearl Grimes,3 John E. Harris,4 Nanja van Geel,5 Davinder Parsad,6 Mukta Tulpule,7 Jackie Gardner,8 Yan Valle,9 Gaone Tlhong Matewa,10 Christine LaFiura,11 Haobo Ren2 and Khaled Ezzedine
doi : 10.1093/bjd/ljad245
Validity, reliability, responsiveness and interpretability of the Recap of atopic eczema (RECAP) questionnaire
Junfen Zhang ,1 Aviël Ragamin ,2 Geertruida L.E. Romeijn ,1 Laura Loman ,1 Jart A.F. Oosterhaven 1 and Marie L.A. Schuttelaar
doi : 10.1093/bjd/ljad247
Comprehensive profiling identifies tumour and immune microenvironmental differences in clinical subsets of cutaneous squamous cell carcinoma
Alesha A. Thai,1,2,3 Richard J. Young,3 Mathias Bressel,2,4 Christopher Angel,5 Lachlan McDowell,6 Albert Tiong,6 Nicholas W. Bucknell,6 Andrew Fellowes,5,7 Huiling Xu,5,7 Anna Trigos,2,3 Danny Rischin1,2 and Benjamin J. Solomon
doi : 10.1093/bjd/ljad250
Boost of innate immunity cytokines as biomarkers of response to extracorporeal photopheresis in patients with leukaemic cutaneous T-cell lymphoma
Yi-Chien Tsai,1 Tanja Schlaepfer,2 Desislava Ignatova,2 Yun-Tsan Chang,1 Alan Valaperti,3 Boyko Amarov,4 Gabriela Blanchard,1 Kevin Pehr,5 Maya Vonow-Eisenring,3 Mirjana Urosevic-Maiwald,6 Wolfram Hoetzenecker,7 Steve Pascolo,2 Christoph Iselin,1 Christina Fassnacht,2 Florentia Dimitriou,2 Malgorzata Bobrowicz8 and Emmanuella Guenova
doi : 10.1093/bjd/ljad220
Prognostic factors for primary cutaneous anaplastic large-cell lymphoma: a multicentre retrospective study from Japan
Tomomitsu Miyagaki,1,2 Norihito Inoue,3 Hiroaki Kamijo,1 Hikari Boki,1 Naomi Takahashi-Shishido ,1 Hiraku Suga,1 Takatoshi Shimauchi,4 Eiji Kiyohara,5 Yoji Hirai,6 Kentaro Yonekura,7 Kengo Takeuchi3 and Makoto Sugaya
doi : 10.1093/bjd/ljad266
How to define a ‘super-responder’ to biologics in psoriasis studies
Sarah E. Thomas ,1Juul M.P.A. van den Reek ,1 Marieke M.B. Seyger 1 and Elke M.G.J. de Jong
doi : 10.1093/bjd/ljad280
Public views are needed for skin colour scales
Stephanie J. Lax ,1 Amanda Roberts,1,2,3 Eleanor Cliffe,1 Grishma Ramesh,1 Dija Ayodele,4 Hywel C. Williams ,1 Sharon Belmo 5 and Paul Leighton 1; on behalf of the Centre of Evidence Based Dermatology Patient Panel
doi : 10.1093/bjd/ljad189
Healthcare experiences among patients with hidradenitis suppurativa: a qualitative study
Yacine Sow ,1 Nicole Salame ,2 Meron R. Siira ,2 Nyla Flowers,2 Amit Garg ,3 Rachel E. Patzer ,2 Dio Kavalieratos ,2 Kimberly A. Curseen,4 Suephy C. Chen 5 and Lauren A.V. Orenstein
doi : 10.1093/bjd/ljad215
Facial naevus count in the identification of patients at higher risk of melanoma
Roberta Giuffrida ,1 Gustavo Zanin Poletto,2 Fabrizio Guarneri ,1 Claudio Conforti ,3 Claudio Guarneri ,4 Rainer Hofmann-Wellenhof 5 and Iris Zalaudek
doi : 10.1093/bjd/ljad216
Increased risk of depression in patients with discoid lupus erythematosus: a nested, case–control study in the All of Us Research Program
Gloria F. Chen ,1 Katharina S. Shaw ,2 Stephanie Sanchez-Melendez ,2 Ruth Ann Vleugels 2 and Jeffrey M. Cohen
doi : 10.1093/bjd/ljad239
Targeted anti-interleukin-17 therapy for linear porokeratosis
Donglin Li ,1 Kristin Technau-Hafsi,1 Katrin Giehl,2 Peter H. Hoeger3 and Cristina Has
doi : 10.1093/bjd/ljad223
Comparison of idiopathic and drug-induced epidermal necrolysis in children
Anne Welfringer-Morin,1,2 Pauline Bataille,1 David Drummond,3 Nathalia Bellon,1,2 Saskia Ingen-Housz-Oro ,2,4 Julie Bonigen ,5 Sophie Schmartz,3 Laura Giraud-Kerleroux,4 Florence Moulin,5 Laure De Saint Blanquat,5 Dominique Bremond-Gignac,6 Smail Hadj-Rabia1 and Christine Bodemer
doi : 10.1093/bjd/ljad226
Time to reconsider skin cancer-related follow-up visits
Anna M. Smak Gregoor , Sven van Egmond , Tamar E.C. Nijsten and Marlies Wakkee
doi : 10.1093/bjd/ljad241
The impact of biologic therapy for moderate-to-severe psoriasis on the immune responses to SARS-CoV-2 infection and vaccination
Rebecca Favaro ,1,2 Alessandra Formai ,1,2 Giulia Pavia ,1,2 Luigi Gargiulo ,1,2 Jessica Avagliano ,2 Mario Valenti ,1,2 Paola Facheris ,2 Beatrice Salsano ,1 Roberta V. Latorre ,1,3 Francesco Bellinato ,4 Paolo Gisondi ,4 Alessandra Narcisi 2 and Antonio Costanzo
doi : 10.1093/bjd/ljad242
Comparative analysis of immune-related adverse events among patients with melanoma on immune checkpoint inhibitors: a retrospective cohort study
Catherina X. Pan ,1,2 Daniel Y. Kim,1,2 Charles B. Lau,2,3 William C. Lau,2,4 Rachael Rowley,2 Ruhi Kanwar,1,2 Nicole R. LeBoeuf1,2,5 and Vinod E. Nambudiri
doi : 10.1093/bjd/ljad271
Blood-based scoring systems for identifying significant liver fibrosis in patients with psoriasis
Leena Chularojanamontri ,1 Waratchaya Panjapakkul ,1 Chayada Chaiyabutr ,1 Chutipon Pruksaeakanan ,1 Supisara Wongdama ,1 Surachanee Likittanasombat ,1 Wimolrak Bandidniyamanon ,2 Christopher E.M. Griffiths 3 and Phunchai Charatcharoenwitthaya
doi : 10.1093/bjd/ljad269
Postzygotic gain-of-function variants in FGFR2 in two patients with hair follicle naevus
Qing Cheng,1 Fang Yang ,2 Ruzeng Xue,1 Huijun Wang 1 and Zhimiao Lin
doi : 10.1093/bjd/ljad267
Spatial transcriptomic profiling reveals the pathophysiology of early-stage hidradenitis suppurativa
Christine Suh-Yun Joh ,1 Soyoung Jeong ,1 Cheol Lee ,2 Hee Jung Lee ,3 Jung Ho Lee ,1 Hyun Seung Choi ,1 Soyun Cho ,4,5,6 Gwangil Kim ,7 Jaehwan Kim ,8,9,10 James G. Krueger ,8 Chung-Gyu Park ,1,11,12 Jung U. Shin ,3 Seon-Pil Jin 5,6,13 and Hyun Je Kim 1
doi : 10.1093/bjd/ljad274
A method for assessing rater reliability in applying the Vitiligo Area Scoring Index
Nishant Kumar,1 Aunna Pourang,1 Nneamaka Ezekwe, 1,2Angela Parks-Miller,1 Tasneem F. Mohammad,1 Richard H. Huggins,1 Linda S. Deal,3 Tatjana Lukic,3 Fan Zhang,4 Henry W. Lim,1 Iltefat Hamzavi1 and Indermeet Kohli1,
doi : 10.1093/bjd/ljad285
Insights into Stevens–Johnson syndrome/toxic epidermal necrolysis lifetime burden: assessing life expectancy, healthcare costs and quality of life
Yi Liu,1 Qing Li,2 Chenyu Chu1 and Yin Zhou
doi : 10.1093/bjd/ljad256
Correction to: Validation of a microRNA liquid biopsy assay for diagnosis and risk stratification of invasive cutaneous melanoma
doi : 10.1093/bjd/ljad288
Correction to: Partner bereavement and risk of psoriasis and atopic eczema: cohort studies in the U.K. and Denmark, and to: Partner bereavement and risk of chronic urticaria, alopecia areata and vitiligo: cohort studies in the UK and Denmark
doi : 10.1093/bjd/ljad338
Correction to: Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb randomized double-blind vehicle-controlled parallel-group study
doi : 10.1093/bjd/ljad340
Correction to: The aggressive behaviour of squamous cell carcinoma in epidermolysis bullosa: analysis of clinical outcomes and tumour characteristics in the Dutch EB Registry
doi : 10.1093/bjd/ljad341
Correction to: TMEM232 promotes the inflammatory response in atopic dermatitis via the nuclear factor-κB and signal transducer and activator of transcription 3 signalling pathways
doi : 10.1093/bjd/ljad346
A study of the safety and effectiveness of lirentelimab as a treatment for people with indolent systemic mastocytosis
doi : 10.1093/bjd/ljad351
Safety and effectiveness of amlitelimab, a potential new treatment for atopic dermatitis: results of a clinical trial
doi : 10.1093/bjd/ljad357
Comparison of risankizumab with apremilast for the treatment of moderate psoriasis
doi : 10.1093/bjd/ljad349
Views on vitiligo disease course and treatment among people living with vitiligo and healthcare providers worldwide
doi : 10.1093/bjd/ljad350
Greater understanding about interpreting the Recap of atopic eczema (RECAP) questionnaire
doi : 10.1093/bjd/ljad359
The effect of extracorporeal photopheresis on cytokines released by leukaemic cutaneous T-cell lymphoma
doi : 10.1093/bjd/ljad358
Multiple skin lesions, especially on the legs, predict a poorer prognosis in skin lymphoma with large tumour cells
doi : 10.1093/bjd/ljad354
